A 67-year-old male with Stage IV non–small cell lung cancer (NSCLC) experienced disease progression following standard-of-care therapies. A comprehensive circulating tumor DNA (ctDNA) genomic panel failed to identify actionable alterations, leaving no clear targeted treatment options. Based on clinical trajectory, estimated life expectancy was limited (on the order of months), and care was approaching a palliative setting.x